alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 10.1


 





FIRST AMENDMENT TO


ASSET PURCHASE AGREEMENT


 


This First Amendment (the “Amendment”)
to the Asset Purchase Agreement (“Agreement”) is made and entered into on November 30, 2015, and shall
be effective as of September 24, 2014, by and between


 


		(1)	AstraZeneca Pharmaceuticals LP, a Delaware limited partnership with offices at 1800 Concord Pike,
Wilmington, Delaware 19803 (“Seller”); and



 


		(2)	IGI Laboratories, Inc.(now Teligent, Inc.), a Delaware Corporation, (“Buyer”).



 


Recitals



 


WHEREAS, the parties desire to amend, modify
and restate certain terms and conditions of the Agreement.


 


Agreement


 


NOW, THEREFORE, in consideration of the
mutual covenants contained in this Amendment, and other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the parties, intending to be legally bound, agree as follows:


 


		1	Definitions



 


Any capitalized term not separately defined
in this Amendment shall have the meaning ascribed to it in the Agreement.




 


		2	Modifications



 


  Section 2.3.3(c) of the Agreement shall be amended to read as follows:




 


(c)Notwithstanding
anything contained herein to the contrary, Buyer may at any time prior to June 30, 2016 elect to satisfy in full its royalty obligations
hereunder by providing Seller written notice of such election and paying to Seller a single payment in an amount equal to $3,000,000
(the “Buy-Out Payment”). Buyer’s payment to Seller of the Buy-Out Payment shall be in lieu of and in full
and final satisfaction of any and all Royalty Payments hereunder.


 


		3	Counterparts 



 


  This Amendment may be executed in two or more counterparts, each of which shall be deemed an original and all of which shall together be deemed to constitute one agreement. The parties agree that execution of this Amendment by exchanging facsimile or PDF signatures shall have the same legal force and effect as the exchange of original signatures.




 






     


     


    

 


		4	Entire Agreement



 


  This Amendment, together with the Agreement, constitutes the entire agreement between the parties with respect to the subject matter of the Agreement. The Agreement together with this Amendment supersedes all prior agreements, whether written or oral, with respect to the subject matter of the Agreement, as amended. All Attachments referred to in this Amendment are intended to be and are hereby specifically incorporated into and made a part of the Agreement. The parties hereby agree that subject to the modifications specifically stated in this Amendment, all terms and conditions of the Agreement, as amended, shall remain in full force and effect.




 


Each party is signing this Amendment on
the date stated opposite that party's signature.


 





	IGI Laboratories, Inc.(Now Teligent, Inc.)	 	AstraZeneca Pharmaceuticals LP
	 	 	 	 	 
	By:	/s/ Jenniffer Collins	 	By:	/s/ Paul Hudson
	 	 	 	 	 
	Name:	Jenniffer Collins	 	Name: 	Paul Hudson
	 	 	 	 	 
	Title: 	CFO	 	Title: 	EVP north america
	 	 	 	 	 
	Date:	November 30, 2015	 	Date: 	November 30, 2015


 






    	 	2
| 1.   | The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and |
|----------------|--------------------------------------------------------------------------------------------------------------|

| 2.   | The information contained in the Report fairly presents, in all material respects, the consolidated financial condition of the Company as of the dates presented and the consolidated result of operations of the Company for the periods presented. |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   By: |   /s/ Berge Abajian                                              |
|-----------------|----------------------------------------------------------------------------|
|  Name:     |  Berge Abajian                                                        |
|  Title:    |  Principal Executive Officer,Principal Financial Officer and Director |
|  Date:     |  May 13, 2010                                                         |
[Federal Register Volume 73, Number 24 (Tuesday, February 5, 2008)]
[Notices]
[Pages 6726-6727]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 08-478]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES


National Committee on Vital and Health Statistics: Meeting

    Pursuant to the Federal Advisory Committee Act, the Department of

[[Page 6727]]

Health and Human Services (HHS) announces the following advisory 
committee meeting.

    Name: National Committee on Vital and Health Statistics (NCVHS), 
Executive Subcommittee.
    Time and Date: February 6, 2008 8:30 a.m.-5 p.m.; February 7, 
2008 8:30 a.m.-12 p.m.
    Place: The L'Enfant Plaza Hotel, 480 L'Enfant Plaza, SW., 
Washington, DC 20024.
    Status: Open.
    Purpose: The NCVHS Executive Subcommittee will hold a day and a 
half meeting to review the past year's accomplishments and conduct 
strategic planning for the coming year. On the first day, the 
Subcommittee will review their 2007 activities; discuss current and 
anticipated health data needs, as well as marketing and 
dissemination of the Committee's products. On the morning of the 
second day the Subcommittee will discuss collaborative activities 
with the Board of Scientific Counselors at the National Center for 
Health Statistics, the plans for updating the 21st Century Health 
Statistics, and the upcoming NCVHS 60th anniversary.
    Contact Person For More Information: Substantive program 
information as well as summaries of meetings and a roster of 
committee members may be obtained from Marjorie S. Greenberg, 
Executive Secretary, NCVHS, National Center for Health Statistics, 
Centers for Disease Control and Prevention, 3311 Toledo Road, Room 
2402, Hyattsville, Maryland 20782, telephone (301) 458-4245. 
Information also is available on the NCVHS home page of the HHS Web 
site: http://www.ncvhs.hhs.gov/, where further information including 
an agenda will be posted when available.
    Should you require reasonable accommodation, please contact the 
CDC Office of Equal Employment Opportunity on (301) 458-4EEO (4336) 
as soon as possible.

    Dated: January 28, 2008.
James Scanlon,
Deputy Assistant Secretary for Science and Data Policy, Office of the 
Assistant Secretary for Planning and Evaluation.
[FR Doc. 08-478 Filed 2-4-08; 8:45 am]
BILLING CODE 4151-05-M
National Institute for Occupational Safety and Health

Program Update

Grady Calhoun, CHP

Director

Advisory Board on Radiation and Worker Health, 132nd Meeting

Oakland, CA | December 11, 2019
Contracts, staffing

 Worker outreach contract awarded

 Hired one Health Physicist still working on two more due to retirements
Workshops, Town Halls and Outreach activities

Since August 2019

 Dose reconstruction workshop in Cincinnati, OH in September

 Town Hall September in Bollingbrook, IL for ANL-E workers

Upcoming outreach, workshop

 NIOSH to attend December 5 DOL outreach – Amarillo, TX (Pantex)

 NIOSH to attend February DOL outreach – Santa Fe, NM (LANL)
Case status report (current as of August 14, 2019)

 51,576 cases to NIOSH from DOL with 49,524 returned to DOL

– 1,143 at NIOSH for DR

– 909 administratively closed

 49,524 submitted with DR to DOL

– 1,628 pulled from DR by DOL

– 3,535 pulled for Special Exposure Cohort (SEC)
Records to Department of Energy

 159 outstanding

 2 more than 60 days
Probability of Causation Summary

 44,361 DRs sent for final adjudication

– 12,155 greater than 50 percent

– 32,206 less than 50 percent 
Active Cases

 1,139 active at NIOSH for DR

– 384 in the DR process

– 221 initial draft DR reports with claimants

– 534 cases preparing for DR
0

50

100

150

200

250

1/6/2012 1/6/2013 1/6/2014 1/6/2015 1/6/2016 1/6/2017 1/6/2018 1/6/2019

# of Cases

Age of Cases 2012-19

> 1 yr 9-12 mo 6-9 mo
0

10

20

30

40

50

60

70

# of cases

Age of Cases 2019

> 1 yr 9-12 mo 6-9 mo
| 1. | Such      Quarterly Report on Form 10-Q for the period      ending September  30, 2008, fully complies with the requirements      of section 13(a) or 15(d) of the Securities Exchange Act of 1934;      and |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2. | The      information contained in such Quarterly Report on Form 10-Q for      the period ending September  30, 2008, fairly presents, in      all material respects, the financial condition and results of operations      of Formulawon,      Inc. |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Date:      November 10, 2008 |
|-----------------------------------|

| By:    | /s/      Fitra Iriani                                                                                                                           |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------|
|   | Fitra      Iriani                                                                                                                               |
|   | Chairman      of the Board of Directors,Chief      Executive Officer, Chief      Financial Officer,Controller,      Principal AccountingOfficer |
Report to the Advisory Board 

on 

Radiation and Worker Health 

December 11, 2012 
Subcommittee Members
  Wanda I. Munn (Chair)
 

Josie Beach
 

Richard A. Lemen 

Paul L. Ziemer
 
 

 

Examples of Current Activities
 

 Procedure Evaluation Reviews 

 Internal Guidance documents 

 Program Procedures 

 OCAS Technical Information Bulletins
Presented at the ABRWH meeting 

Kansas City MO 

January 28, 2014 
Work Group Members 

 Paul Ziemer, Chair 

 Josie Beach 

 John Poston 

 Wanda Munn 
Recommendation on Extending Period 

of SEC Class by 7 Months 

The Work Group, by unanimous vote, agrees with NIOSH 

that dose can not be reconstructed for the period January 

1, 1948 through July 31, 1948, and recommends that this 

time period should be included in the SEC class definition 

previously approved by the Board. 
Recommendation on Denying SEC 

Class Status for the 

Remainder of the Covered Period 

By unanimous vote, the Work Group agrees with NIOSH 

that dose can be reconstructed for the remainder of the 

covered period (i.e., beginning August 1, 1948) and that SEC 

class status should not be recommended for work during 

that time period. 
Status of Issues Matrix for Joslyn 

 The SC&A Issues Matrix for Joslyn included 11 findings. 

 The Work Group, by unanimous agreement, closed 8 of 

the findings. 

 The Work Group agreed that the remaining issues 

(Numbers 6, 10, and 11) were not SEC issues and would 

not, therefore, affect the recommendation concerning 

the SEC. 

 The Work Group expects to be able to close these last 

three items soon on the basis of a White Paper that 

NIOSH has agreed to produce. 
Summary of Matrix Issues 

1. Incorrect units of measure in Table 6-1. Agreed & closed. 

2. Incorrect units of measure in Table 6-2. Agreed & closed. 

3. Document 1948 as start date (for site surveys). Resolved 

by establishment of new start date (August 1, 1948). 

Closed. 

4. Correct Table 7-1 to assure comparable units and correct 

work hours. Agreed & closed. 

5. Correct the typographical and calculational errors in Table 

7-2. Agreed and closed. 

6. Inadequate description of how TBD-6000 dose 

reconstruction methods are to be applied. NIOSH 

preparing White Paper to address this. OPEN 
Summary of Matrix Issues (continued) 

 

7. Address uncertainty as to whether air concentration rates are 

dependent on production rates. Issue now moot since it dealt 

with early 1948 (which is now included in the SEC). 

8. Evaluate degree to which pit burning of uranium renders TBD6000 incomplete as a surrogate. NIOSH White Paper addressed 

issue; SC&A concurred, and issue was closed. 

9. Document basis for 90% coverage of uranium source term. 

Agreed and closed. 

10. Need revised external exposure assumptions. This finding is 

closely tied to Issue 6 and will be addressed by NIOSH in White 

Paper. OPEN 

11. NIOSH should document sources of information on relative 

hazard from thorium. NIOSH agreed to provide details. OPEN
EXHIBIT
32.2





CERTIFICATION
PURSUANT TO


18
U.S.C. SECTION 1350,


AS
ADOPTED PURSUANT TO


SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002





In
connection with the Quarterly Report of Global Risk Management &
Investigative Solutions (the “Company”) on Form 10-Q for the period ended March
31, 2009, as filed with the Securities and Exchange Commission on the date
hereof (the “Report”), I, Peter Maheu, Principal Financial Officer, of the
Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, that:





1.
            The
      Report fully complies with the requirements of Section 13(a) or 15(d) of
      the Securities Exchange Act of 1934;
and





2.
            The
      information contained in the Report fairly presents, in all material
      respects, the financial condition and results of operations of the
      Company.











/s/ Peter MaheuPeter
      MaheuPrincipal
      Financial OfficerMay
      20, 2009
1 

AGENDA 

Advisory Board on Radiation and Worker Health – Meeting 112 

Residence Inn by Marriott

635 West Broadway, Idaho Falls, ID 83402 

Phone: (208) 542-0000; Fax: (208) 542-0021 

Teleconference Phone: 866-659-0537, Participant Code: 9933701# 

LiveMeeting Link:

https://www.livemeeting.com/cc/cdc/join?id=M3QDP7&role=attend&pw=ABRWH

Meeting ID: M3QDP Entry Code: ABRWH

Tuesday, August 9, 2016 

NOTE: All times in Mountain Time 

8:15 a.m. – 8:30 a.m. Welcome and Introduction Dr. James Melius, Chair

8:30 a.m. – 8:45 a.m. NIOSH Program Update Mr. Stuart Hinnefeld, NIOSH 

8:45 a.m. – 9:00 a.m. DOL Program Update Mr. Frank Crawford, DOL 

9:00 a.m. – 9:15 a.m. DOE Program Update Dr. Patricia Worthington, DOE

9:15 a.m. – 10:00 a.m. Dose Reconstruction Report to 

the Secretary and Future 

Review Methods

Dr. James Melius, Dose 

Reconstruction Review 

Methods WG Chair

10:00 a.m. – 10:15 a.m. Break

10:15 a.m. – 10:30 p.m. Review of Pinellas Plant Site 

Profile

Mr. Phillip Schofield, 

Work Group Chair

10:30 a.m. – 12:00 p.m. Blockson Chemical Company 

SEC petition (Jolliet IL, 1960-

1991) 

Ms. Wanda Munn, WG Chair

Dr. James Neton, NIOSH 

Petitioner:

12:00 p.m. – 1:30 p.m. Lunch

1:30 p.m. – 3:15 p.m. Board Work Session Dr. James Melius, Chair

3:15 p.m – 3:30 p.m. Break

3:30 p.m. – 5:00 p.m. Idaho National Laboratory 

SEC Petition (Scoville ID)

and Argonne National 

Laboratory West SEC Petition

(Scoville ID)

Mr. Philip Schofield, WG 

Chair

Mr. John Stiver, SC&A 

Petitioners: 
2 

5:00 p.m. – 6:00 p.m.* Public Comment

6:00 p.m. Adjourn, Day 1

* Public comment period will conclude at 6:00 p.m. or following the final call for public comment, 

whichever comes first. If you plan to comment, please be prepared to comment at 5:00 p.m. 

Wednesday, August 10, 2016 

NOTE: All times in Mountain Time

8:15 a.m. – 8:30 a.m. Welcome and Introduction Dr. James Melius, Chair

8:30 a.m. – 9:45 a.m. Westinghouse Electric Co. 

SEC Petition (1960-2011, 

Bloomfield NJ) 

Dr. Henry Anderson, URAWE 

WG Chair 

Petitioner(s):

9:45 a.m. – 10:00 a.m. Break

10:00 a.m. – 10:45 a.m. Review of Site Profile for 

United Nuclear Co. (Hematite 

MO)

Dr. Henry Anderson, URAWE 

WG Chair

10:45 a.m. – 11:30 a.m. Savannah River Site SEC 

Petition Update (1973-2007, 

Aiken SC)

Mr. Stuart Hinnefeld, NIOSH

Petitioner:

11:30 a.m. – 1:00 p.m. Bliss and Laughlin Steel SEC 

Petition (1999, Buffalo NY)

Dr. James Neton, NIOSH

Petitioner(s): 

1:00 p.m. Adjourn
<PAGE>   1
Exhibit 21.1

                           Significant Subsidiaries of
                            Balanced Care Corporation

BCC Development and Management Co.

BCC Investment Corporation

Balanced Care at Butler, Inc.

Balanced Care at Sarver, Inc.

BCC at State College, Inc.

BCC at Darlington, Inc.

Balanced Care at Eyers Grove, Inc.

Balanced Care Realty at Altoona, Inc.

Balanced Care Realty at Berwick, Inc.

Balanced Care Realty at Lewistown, Inc.

Balanced Care Realty at Mansfield, Inc.

Balanced Care Realty at Martinsburg, Inc.

Balanced Care Realty at Sherwood, Inc.

Balanced Care Realty at Maumelle, Inc.

Balanced Care Realty at Mountain Home, Inc.

Balanced Care Realty at Peckville, Inc.

Balanced Care Realty at Reading, Inc.

Balanced Care Realty at Scranton, Inc.

Balanced Care Realty at State College, Inc.

Balanced Care at Merrillville, Inc.

Balanced Care at Morristown, Inc.

BCC at Missouri, Inc.

Balanced Care Therapies of PA, Inc.

Balanced Care Therapies of AR, Inc.
**Exhibit 32.1**

 

**PRINCIPAL EXECUTIVE OFFICER CERTIFICATION**

**PURSUANT TO SECTION 906 OF THESARBANES-OXLEY ACT OF 2002**

 

In connection with the Annual Report of Vita Food Products, Inc.(the “Company”) on Form 10-K for the fiscal year ended December 31,2004, as filed with the Securities and Exchange Commission on the date hereof(the “Report”), the undersigned, in the capacity and on the date indicatedbelow, hereby certifies pursuant to 18 U.S.C. Section 1350, as adoptedpursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: (1) theReport fully complies with the requirements of Section 13(a) or 15(d) ofthe Securities Exchange Act of 1934; and (2) the information contained inthe Report fairly presents, in all material respects, the financial conditionand results of operations of the Company.

 

 
| Date:  March 28, 2005 | By:    |    /s/  Stephen D. Rubin |   |
|---------------------------------|--------|----------------------------------------------|--------|
|                            |   | Stephen D. Rubin,                            |   |
|                            |   | President                                    |   |
|                            |   | (Principal  Executive Officer)               |   |

 

1

----
**EXHIBIT 32.1**

 

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

 

In connection with the Amendment No. 1 to theAnnual Report on Form 10-KSB/A of World Heart Corporation (the “Corporation”)for the year ended December 31, 2005 as filed with the Securities andExchange Commission on the date hereof (the “Report”), the undersigned,Jal S. Jassawalla, President and Chief Executive Officer of theCorporation, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adoptedpursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to myknowledge:

 

(1)           TheReport fully complies with the requirements of Section 13(a) or 15(d) of theSecurities Exchange Act of 1934 as amended; and

 

(2)           Theinformation contained in the Report fairly presents, in all material respects,the financial condition and results of operations of the Corporation as ofDecember 31, 2005.

 

 
| Dated: April 26, 2006 |   | /s/ * Jal S. Jassawalla                 |   |
|-----------------------|--------|-----------------------------------------|--------|
|                  |   | Jal S. Jassawalla,  President and Chief |   |
|                  |   | Executive Officer                       |   |
|                  |   | (Principal Executive  Officer)          |   |

----

*

A signed original of thiswritten statement required by section 906 has been provided to theCorporation and will be retained by the Corporation and furnished to theSecurities and Exchange Commission or its staff upon request.

 

----
AGENDA

Advisory Board on Radiation and Worker Health 

Teleconference of

Idaho National Laboratory WG

January 15, 2016

Conference Phone: 1-866-659-0537; Participant Code: 9933701#

10:30 a.m. Eastern Time Welcome and roll-call/introductions

Work Group Discussion

• Update on DCAS Special Exposure Cohort class definition (Tim Taulbee NIOSH)

• Review of class definition (Bob Barton SC&A)

• Brief update on other DCAS and SC&A SEC activities 

• Petitioner Comments

• Work Group recommendation(s) and plans for January or March Board meeting

Adjourn
EXHIBIT 32


CERTIFICATION PURSUANT TO SECTION 906

Pursuant to 18 U.S.C. Section 1350 as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, I, the
undersigned officer of the Bayrock Ventures, Inc.
(the "Company"), hereby certify to my knowledge that:

The Report on Form 10-Q for the period ended September 30,
2009 of the Company fully complies, in all material respects,
with the requirements of Section 13(a) or 15(d) of the Securities
Exchange Act of 1934, and the information contained in the
Report fairly represents, in all material respects, the
financial condition and results of operations of the Company.

A signed original of this written statement required by Section
906 has been provided to the Company and will be retained by
the Company and furnished to the Securities and Exchange
Commission or its staff upon request.


                                 /s/ Pavel Alpatov
                                 ----------------------------
                          By:    Pavel Alpatov
                          Title: President and Director and
                                 Chief Executive Officer,
                                 Chief Financial Officer and
                                 Principal Accounting Officer
Date: October 28, 2009
DAVIS SERIES, INC.
2949 East Elvira Road, Suite 101
Tucson, Arizona 85706
(520) 434-3771

CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2003



KENNETH C. EICH, Principal Executive Officer, and SHARRA L. REED, Principal
Financial Officer of Davis Series, Inc. (the "Registrant"), each certify to the
best of his or her knowledge that:

(1) The Registrant's periodic report on Form N-CSR for the period ended
    June 30, 2003 (the "Form N-CSR") fully complies with the requirements of
    Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended;
    and

(2) The information contained in the Form N-CSR fairly presents, in all
    material respects, the financial condition and results of operations of the
    Registrant.

Principal Executive Officer                     Principal Financial Officer

DAVIS SERIES, INC.               		DAVIS SERIES, INC.

/s/ Kenneth C. Eich				/s/ Sharra L. Reed

Kenneth C. Eich                                 Sharra L. Reed
Principal Executive Officer                     Principal Financial Officer
Date:  August 29, 2003                          Date: August 29, 2003


A signed original of this written statement required by Section 906 of the
Sarbanes-Oxley Act of 2003 has been provided to DAVIS SERIES, INC. and will be
retained by DAVIS SERIES, INC. and furnished to the Securities and Exchange
Commission (the "Commission") or its staff upon request.

This certification is being furnished to the Commission solely pursuant to
18 U.S.C. Section 1350 and is not being filed as part of the Form N-CSR filed
with the Commission.